Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 9.6 | 9.7 | 9.3 | 10.0 | 9.1 | 11.2 | 11.5 | 12.5 |
| Operating profit | $bn | 1.43 | 1.82 | ||||||
| Net profit | $bn | 0.41 | 0.83 | 0.85 | 0.08 | 0.00 | 0.96 | 0.65 | 1.85 |
| EPS reported | $ | 2.09 | 1.49 | ||||||
| Operating cashflow per share | $ | 3.70 | 4.42 | ||||||
| Capex per share | $ | 1.82 | 1.93 | ||||||
| FCF per share | $ | 1.88 | 2.49 | ||||||
| Free cash flow | $bn | 0.81 | 1.08 | ||||||
| Net debt | $bn | 3.56 | 4.97 | ||||||
| Book value equity | $bn | 9.38 | 9.02 | ||||||
| Book value per share | $ | 21.48 | 20.58 | ||||||
| Number of shares | m | 436.8 | 438.4 | ||||||
| DPS (TTM paid) | $ | 1.02 | 1.02 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 34.91 | - | ||||||
| P/B LTM | x | 3.35 | 4.07 | ||||||
| P/S LTM | x | 2.82 | 3.18 | ||||||
| P/FCF LTM | x | 38.83 | 33.95 | ||||||
| EV/EBITDA LTM | x | 15.47 | 17.81 | ||||||
| EV/Sales LTM | x | 3.17 | 3.61 | ||||||
| Earnings Yield LTM | % | 2.86% | 1.76% | ||||||
| FCF Yield | % | 2.58% | 2.95% | ||||||
| Quality | |||||||||
| ROE | % | 10.20% | 7.04% | ||||||
| ROIC | % | 6.83% | 8.78% | ||||||
| Operating margin | % | 12.77% | 15.79% | ||||||
| Gross margin | % | 47.36% | 47.54% | ||||||
| FCF/Sales | % | 7.26% | 9.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | +186.54% | ||||||
| Sales Growth YoY | % | +22.32% | +23.77% | ||||||
| Net Income Growth YoY | % | - | +185.62% | ||||||
| FCF Growth | % | +1250.0% | +242.33% | ||||||
| Operating Profit Growth | % | +364.17% | +27.99% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.00% | 1.22% | ||||||
| Dividend Growth | % | +39.99% | +39.99% | ||||||
| Payout Ratio | % | 34.51% | 32.90% | ||||||
| FCF/Debt | x | 0.14 | 0.17 | ||||||
| Net Debt/EBITDA | x | 1.72 | 2.12 | ||||||
| EBIT/Net interest | x | 6.48 | 8.45 | ||||||
| Net debt/market cap | % | 11.31% | 13.47% | ||||||
| Net debt/Equity | x | 0.38 | 0.55 | ||||||
| Gross debt/equity | x | 0.61 | 0.69 | ||||||
ETFs that hold Sandoz Group
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares MSCI Europe Mid Cap UCITS ETF | EUMD.L | 3 | 1.53% |
| BMO MSCI EAFE Small-Mid Cap Index ETF | ZESM.TO | 5 | 0.45% |
| Deka MSCI Europe MC UCITS ETF | EL43.DE | 3 | 1.52% |
Funds with Sandoz Group among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares MSCI Europe Mid Cap UCITS ETF | EUMD.L | 3 | 1.53% |
| BMO MSCI EAFE Small-Mid Cap Index ETF | ZESM.TO | 5 | 0.45% |
| Deka MSCI Europe MC UCITS ETF | EL43.DE | 3 | 1.52% |
Funds with Sandoz Group among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free